While PD(L)-1 inhibition is clinically efficacious in many cancer types, PD-L1 expression poorly predicts clinical benefit, emphasizing the demand for clinical trials evaluating efficacy as well as the need for better biomarkers of treatment response (100). This evidence concerns the gene CD274 and cancer.